SCHEMBL30765874

SCHEMBL30765874

Nc1cnc(N2CCOCC2)n(CC(=O)NCc2cc3cnccc3n2S(=O)(=O)c2ccccc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.41
NAMPT P43490 8/20 0.37
NTRK3 Q16288 1/20 0.36
F2 P00734 1/20 0.35
PRSS1 P07477 1/20 0.35
MTNR1B P49286 1/20 0.34
IDE P14735 1/20 0.34
PIK3CA P42336 2/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
AKT1 P31749 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765520 0.87 NTRK1 (0.41) NTRK1NAMPTNTRK3F2PRSS1
SCHEMBL30765718 0.86 NTRK1 (0.45) NTRK1NTRK3F2PRSS1MTNR1B
SCHEMBL30765865 0.86 NTRK1 (0.37) NTRK1NAMPTF2PRSS1IDE
SCHEMBL30765506 0.84 NTRK1 (0.51) NTRK1NTRK3
SCHEMBL30765852 0.84 NTRK1 (0.38) NTRK1NAMPTNTRK3F2
SCHEMBL30765715 0.82 ATM (0.40) MTNR1BALDH1A1KDM4E
SCHEMBL30765816 0.77 NTRK1 (0.38) NTRK1NAMPTNTRK3
SCHEMBL30765486 0.74 NTRK1 (0.33) NTRK1ALDH1A1L3MBTL1
SCHEMBL31558522 0.72 MTNR1B (0.45) NTRK1NAMPTMTNR1BIDEPIK3C3
SCHEMBL32680681 0.70 ALDH1A1 (0.50) NTRK1NAMPTMTNR1BIDEPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed